Why Eli Lilly Stock is Down 33% in 2023: 4 Key Reasons
Eli Lilly (LLY) stock has plunged 33% in 2023, significantly underperforming the broader market. Several factors have contributed to this decline, including: 1. Patent Expiration and Generic Competition Eli Lilly’s blockbuster drug, Trulicity, is set to lose patent protection in 2025, paving the way for generic competition. Trulicity generated $7.7 billion in revenue in 2022,…
